Zonisamide

Zonisamide
Clinical data
Trade names	Zonegran, Zonisade
AHFS/Drugs.com	Monograph
MedlinePlus	a603008
License data	US DailyMed: Zonisamide;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	N03AX15 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	~100%
Protein binding	40%
Metabolism	Liver through CYP3A4
Elimination half-life	63 hours in plasma
Excretion	Kidney (62%); Faeces (3%)
Identifiers
	IUPAC name benzo[d]isoxazol-3-ylmethanesulfonamide;
CAS Number	68291-97-4 ;
PubChem CID	5734;
IUPHAR/BPS	7047;
DrugBank	DB00909 ;
ChemSpider	5532 ;
UNII	459384H98V;
KEGG	D00538 ;
ChEBI	CHEBI:10127 ;
ChEMBL	ChEMBL750 ;
PDB ligand	ZON (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID9046023 ;
ECHA InfoCard	100.118.526
Chemical and physical data
Formula	C8H8N2O3S
Molar mass	212.22 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	162 °C (324 °F)
	SMILES O=S(=O)(N)Cc2noc1ccccc12;
	InChI InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) ; Key:UBQNRHZMVUUOMG-UHFFFAOYSA-N ;
	(verify)

Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. Chemically it is a sulfonamide. It serves as an anticonvulsant used primarily as an adjunctive therapy in adults with Parkinson's disease, partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic and generalized tonic clonic seizure. Despite this it is also sometimes used as a monotherapy for partial-onset seizures.

In 2020, it was the 276th most commonly prescribed medication in the United States, with more than 1 million prescriptions.